Health Care
Pharmaceuticals
Largecap
With a market cap of ₹88,870 cr, stock is ranked 60
Stock has been generating better return on equity than bank FD
Stock doesn't offer attractive dividend returns
Good time to consider, as stock is not in overbought zone
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Disclaimer : I am not a SEBI Registered Research Analyst so before your Investment Please Consult you Financial adviser.